Communications Biology
April 18, 2025
S Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al.
17 citations
Psychedelics offer a profound window into the human brain through their robust effects on perception, subjective experience, and brain activity patterns. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) induces a profoundly immersive altered state of consciousness lasting under 20 min, allowing the entire experience to be captured during a single functional magnetic resonance imaging...
Schizophrenia Bulletin
April 17, 2025
Nathan H. Heller, Frederick S. Barrett, Tobias Buchborn et al.
3 citations
Abstract Background and Hypothesis Visual hallucinations (VH) are a core symptom of both Lewy body diseases (LBDs; eg, Parkinson’s disease and dementia with Lewy bodies) and serotonergic psychedelics (SPs; eg, psilocybin and mescaline). While these conditions differ in etiology, overlapping phenomenology, and neural mechanisms suggest shared pathways. This review explores similarities and...
Renal Replacement Therapy
April 15, 2025
Kazuhiro Okamoto, Nobuhiro Hashimoto, Kaiya Ishizeki et al.
Dextromethorphan (DXM) misuse, particularly among young individuals, has risen owing to its euphoric and hallucinogenic effects. High-dose DXM ingestion can trigger serotonin syndrome, a condition characterized by psychiatric, neuromuscular, and autonomic symptoms. In severe cases, serotonin syndrome may result in rhabdomyolysis and acute kidney injury (AKI). However, reports of severe...
Naunyn-Schmiedeberg's Archives of Pharmacology
April 15, 2025
Arya Afrooghe, Elham Ahmadi, Ali Lesani et al.
We aimed to investigate whether psilocin, the bioactive metabolite of the well-known psychedelic, psilocybin, may have antipruritic effects in mice by interfering with the kynurenine pathway and interacting with 5-HT2A receptors. Eight mice were randomly assigned to each of the study groups receiving either normal saline, compound 48/80, psilocin (0.3, 1, and 3 mg/kg), or psilocin (1 mg/kg) +...
International Journal of Science and Research (IJSR)
April 3, 2025
David Nisenboim
Medical treatment for behavioral disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD) represent emerging challenges in the field and have been a subject of studies for a long time. Available therapeutics include selective serotonin reuptake inhibitors (SSRIs), Monoamine oxidase inhibitors (MAOIs), tricyclics, etc. Nevertheless, recent studies have identified a...
International Journal of Mental Health and Addiction
April 1, 2025
Joshua C. Black, Nicole Schow, Hannah L. Burkett et al.
3 citations
Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...
Journal of Psychopharmacology
March 31, 2025
Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke et al.
4 citations
Background: Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of “psychedelic afterglow,” a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
March 20, 2025
Zhen Xuen Brandon Low, Shin Jie Yong, Hayam A Alrasheed et al.
In our ongoing battle against the coronavirus 2019 (COVID-19) pandemic, a major challenge is the enduring symptoms that continue after acute infection. Also known as Long COVID, post-COVID-19 syndrome (PCS) often comes with debilitating symptoms like fatigue, disordered sleep, olfactory dysfunction, and cognitive issues ("brain fog"). Currently, there are no approved treatments for PCS. Recent...
European Journal of Pharmacology
March 15, 2025
James J Gattuso, Carey Wilson, Shanshan Li et al.
16 citations
Psilocybin is a serotonergic psychedelic with therapeutic potential for several neuropsychiatric disorders, including depression and anxiety disorders. Serotonin transporter (5-HTT) knockout mice (KO) are a well-validated mouse model of anxiety/depression and are relevant to both chronic treatment with serotonin transporter reuptake inhibitors (SSRIs) and polymorphisms in the serotonin...
ACS Medicinal Chemistry Letters
March 13, 2025
Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel compounds as 5-HT2A receptor modulators, pharmaceutical compositions, use of such compounds in treating psychiatric and neurological disorders and processes for preparing such compounds.